Navigation Links
Meningitis vaccine study gets £200,000 boost
Date:2/7/2008

It can kill in four hours and more than 300 people in the UK die from it every year and hundreds more are left with permanent disabilities. Now researchers will work on a potential vaccine for meningitis B, thanks to a 200,000 grant from the medical charity Meningitis UK.

Although vaccines exist to protect against some strains of meningitis, there is still no vaccine to protect against all strains, including the most common in the UK Group B meningococci. This is responsible for almost 90 per cent of all cases and is most common in children under the age of five.

The team, led by Dr Karl Wooldridge, a lecturer in the Centre for Biomolecular Sciences, aim to develop a vaccine against this strain of the bacterium. Group B meningococci mimic molecules in the human body, which makes developing an effective vaccine against this strain very difficult.

Researchers worldwide are searching for alternative antigens molecules that can stimulate an immune response on the surface of the bacteria, which could be used as a basis for a vaccine against meningitis B.

The team has identified a series of autotransporter proteins proteins which are secreted from the surface of Group B meningococci which could be used to create antibodies that will then kill the bacteria.

The grant will be used to fund a two-year research post, examining each of the proteins produced by the bacteria for the potential to create effective antibodies. The genetic code for each protein will be cloned and tagged, allowing the protein to be produced in large amounts and purified for further study.

If we identify one or more of these proteins that give a good protective response we would ultimately move to human trials, said Dr Wooldridge. This would hopefully demonstrate a positive immune response to the vaccine. By identifying a range of active proteins, rather than just one, we could develop a vaccine that targeted all strains of the Group B meningococci.

Meningitis UK launched its Search 4 a Vaccine Campaign in 2007 to help raise 7million over the next seven years to fund vital work into developing a vaccine against Group B. This innovative project is just one of the studies the charity is funding.

Meningitis UKs Chief Executive Steve Dayman said: We are extremely pleased to be funding Dr Karl Wooldridge and his team in their work to discover more about the proteins secreted by the Meningitis B bacteria. If this research can go forward to help develop a vaccine, thousands of lives could be saved.

Meningitis can be incredibly hard to detect as many of its symptoms are often similar to more minor ailments such as the common cold or flu, plus there are occasions when people show no, or very few, symptoms. For these reasons, we believe the only way to eradicate meningitis completely is through the development of a preventative vaccine.


'/>"/>

Contact: Karl Wooldridge
karl.wooldridge@nottingham.ac.uk
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Schedules Revised for Flu, Meningitis Vaccines
2. New Meningitis Vaccine Works in Infants
3. Steroid Fails to Ease Meningitis in Trials
4. Meningitis Shot Available, Effective Year-Round
5. Tattooing Best Way to Deliver DNA Vaccines
6. Novel molecules developed at UB can boost vaccine potency
7. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
8. Another Study Finds No Link Between MMR Vaccine and Autism
9. New hospital standards needed for pediatric flu vaccines
10. Experimental Vaccine Halts Prostate Cancer in Mice
11. Novel vaccine concept developed by scientists at the Wistar Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
Breaking Medicine Technology: